No Data
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK): subscribed to 0.22 billion yuan Shanghai Pudong Development Bank structured deposit products.
Gelonghui, April 1st | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced that recently, the company signed a structured deposit product agreement with Shanghai Pudong Development Bank, agreeing to purchase structured deposit products totaling 0.22 billion yuan with idle funds generated from daily operations.
Insight into the 2024 Industry Earnings Conference｜The management of Shanghai Pudong Development Bank stated that it will continue to control the cost of deposit interest payments and establish a blacklist mechanism to resolutely exit some customers.
① Xie Wei pointed out that the overall environment remains very challenging, and the trend of narrowing net interest margins will continue. ② Striving to solidify the Crediting customer base within 3 to 5 years to further improve the quality of Crediting Assets. ③ In 2024, the total disposal of non-performing Assets will reach 108.7 billion yuan, with Cash recovery of non-performing Assets at 37.8 billion yuan, both figures hitting historical highs, leading to provision reversal.
Hua Fu Securities: The increase in capital from large banks has landed, enhancing financial support capabilities for the real economy.
The expectation of large banks increasing their capital has long been brewing, and this time the announcement aligns with market expectations.
Shanghai Pudong Development Bank Co., Ltd. 2024 Annual Report
Summary of the 2024 Annual Report of Shanghai Pudong Development Bank Co., Ltd.
Shanghai Pudong Development Bank (600000.SH) released its 2024 annual performance, with a net income of 45.257 billion yuan, an increase of 23.31% year-on-year.
Shanghai Pudong Development Bank (600000.SH) disclosed its 2024 annual report, showing that the company achieved a revenue of 1707....
